Syntara Limited
AASX:SNT0.02
AUD
0.00
(0.00%)
ISIN
AU0000312480
Return %
Stock
S&P 500
1Y
-35.48
14.20
3Y
-37.50
81.12
5Y
-82.61
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Gary Jonathan Phillips
- Full Time Employees
- 85
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 20A Rodborough Road Frenchs Forest NSW Australia 2086
- IPO Date
- Oct 7, 2003
- Website
- syntaratx.com.au
- Similar Companies
- Business
- Syntara Limited operates as a clinical-stage drug developer focused on therapies addressing fibrosis, inflammation, and related conditions, with a portfolio aimed at extracellular matrix dysfunction and inflammatory processes. The company is listed on ASX (ticker SNT) and maintains research-driven programs across multiple phase trials, including candidates targeting myelofibrosis and other fibrotic or inflammatory diseases. Headquarters are in Australia, with additional operations and collaborations spanning international research and development sites. Founded in 2016, Syntara advances its pipeline through a combination of in-house discovery, chemistry expertise in amine oxidase pathways, and strategic partnerships to progress clinical-stage assets toward potential commercialization. Main products and services: clinical-stage drug candidates and development programs across fibrosis, inflammation, and related disorders; preclinical and translational research services; collaborations and licensing activities to accelerate growth; investor relations and corporate communications to support funding and strategic partnerships. Latest major changes: enters strategic partnerships and collaborations to advance its pipeline and leverage external development capabilities; pursues funding rounds and potential acquisitions to support clinical trial progression and expansion of its portfolio; announces new trial initiations or expansions, including additional Phase 2 studies or evaluations of Phase 1b/2 candidates; undergoes corporate actions such as restructurings or name changes to reflect evolving strategic focus; expands geographic footprint and research collaborations to support global clinical development efforts. Industry and segments: biopharmaceuticals with a focus on fibrosis, inflammatory diseases, and related extracellular matrix dysfunction; research and development services; potential diagnostics and companion study opportunities aligned with oncology and hematology indications. Geographic operations: headquarters in Australia; research and development activities and partnerships across Australia, Europe, and North America; potential manufacturing and clinical trial sites in multiple regions as part of ongoing globalization of the development program. Subsidiaries and parent relationships: operates as an independent listed entity on the ASX under SNT; maintains collaborations and licenses with partner institutions and contract research organizations to support pipeline progression. Note: This description reflects Syntara Limited’s public profile as an ASX-listed clinical-stage drug developer focusing on fibrosis and inflammation, incorporating its pipeline, partnerships, and strategic expansion efforts as reported in recent public disclosures and industry coverage.